Scott & Selber Inc. decreased its position in shares of Becton Dickinson and Co (NYSE:BDX) by 3.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,735 shares of the medical instruments supplier’s stock after selling 65 shares during the period. Scott & Selber Inc.’s holdings in Becton Dickinson and were worth $437,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. FMR LLC increased its holdings in shares of Becton Dickinson and by 5.0% in the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock worth $4,453,934,000 after buying an additional 842,590 shares during the period. Ronna Sue Cohen increased its holdings in shares of Becton Dickinson and by 24,129.0% in the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock worth $5,734,000 after buying an additional 5,710,365 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Becton Dickinson and by 10.4% in the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock worth $1,103,526,000 after buying an additional 416,459 shares during the period. Fundsmith LLP increased its holdings in shares of Becton Dickinson and by 0.9% in the first quarter. Fundsmith LLP now owns 3,771,159 shares of the medical instruments supplier’s stock worth $941,772,000 after buying an additional 35,453 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Becton Dickinson and by 0.7% in the first quarter. Northern Trust Corp now owns 3,223,811 shares of the medical instruments supplier’s stock worth $805,082,000 after buying an additional 23,645 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s stock.

In other news, Director Claire Fraser sold 1,429 shares of Becton Dickinson and stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total transaction of $347,618.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Samrat S. Khichi sold 16,085 shares of Becton Dickinson and stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the transaction, the executive vice president now owns 12,608 shares of the company’s stock, valued at $2,958,845.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,529 shares of company stock worth $5,836,116. Insiders own 0.12% of the company’s stock.

Several research analysts have recently commented on the company. Wells Fargo & Co decreased their price objective on Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating on the stock in a report on Monday, May 13th. Morgan Stanley raised their target price on Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 16th. Zacks Investment Research raised Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Monday, May 20th. ValuEngine cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, UBS Group cut their target price on Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, May 10th. Five equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Becton Dickinson and currently has an average rating of “Buy” and an average target price of $264.27.

Becton Dickinson and stock traded up $4.92 during trading hours on Tuesday, hitting $254.08. 50,800 shares of the stock traded hands, compared to its average volume of 1,066,327. The business’s 50-day moving average price is $251.93. The company has a current ratio of 1.09, a quick ratio of 0.67 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $68.66 billion, a P/E ratio of 23.07, a PEG ratio of 1.85 and a beta of 1.11. Becton Dickinson and Co has a one year low of $208.62 and a one year high of $265.87.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.05 by $0.03. The business had revenue of $4.35 billion for the quarter, compared to analysts’ expectations of $4.37 billion. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The business’s revenue was up 1.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.91 EPS. On average, equities research analysts predict that Becton Dickinson and Co will post 11.68 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, September 6th. This represents a $3.08 annualized dividend and a yield of 1.21%. Becton Dickinson and’s payout ratio is 27.97%.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: Short Selling Stocks and Day Traders

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.